Combination Drug Therapy Shows Promise for Recurrent Endometrial Cancer
Researchers seeking to improve treatment outcomes for women with recurrent endometrial cancer – the most commonly diagnosed gynecologic malignancy in the U.S., killing more than 8,000 women each year – have reported positive results through targeted therapy that uses a combination of the drugs everolimus and letrozole. Their findings have been reported in the Journal of Clinical Oncology.
